This NDC is on FDA's drug shortage list (posted Jan 24, 2025)
Reported reason: Regulatory delay
Product Information
PEGASYS 180 MCG/ML VIAL is a brand product labeled by pharmaand GmbH, priced at $1070.9040 per ML under NDC 82154044901. Its NADAC has been published 78 times since Oct 23, 2024.
Strength
180 ug/mL
Manufacturer
pharmaand GmbHNDC
82154044901
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
4/23/2025
Active Ingredients
PEGINTERFERON ALFA-2AApproval Type
Biologic (BLA)
FDA Application
BLA103964On Market Since
10/16/2002
Pharmacological Classes
Price Statistics
The NADAC for PEGASYS 180 MCG/ML VIAL has been published 78 times since Oct 23, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1070.9040 per ML |
|---|---|
| All-time high | $1070.9040 (Apr 15, 2026) |
| All-time low | $1070.9040 (Oct 23, 2024) |
| 52-week high | $1070.9040 |
| 52-week low | $1070.9040 |
| Median price | $1070.9040 |
| Average price | $1070.9040 |
| Largest weekly change | 0.0% (Oct 30, 2024) |
| Weeks tracked | 78 |
| Tracking since | Oct 23, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
0.0%
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Apr 15, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the peginterferon alfa-2a market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of PEGASYS 180 MCG/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for PEGASYS 180 MCG/ML VIAL, manufactured by pharmaand GmbH, is $1070.9040 per ML (NDC 82154044901), effective Apr 15, 2026.
How has the price of PEGASYS 180 MCG/ML VIAL changed over time?
Over the history we have for it, the NADAC for PEGASYS 180 MCG/ML VIAL has held within roughly two percent of its current level. It has been tracked across 78 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for PEGASYS 180 MCG/ML VIAL?
Since Oct 23, 2024, the NADAC for PEGASYS 180 MCG/ML VIAL has ranged from a low of $1070.9040 (Oct 23, 2024) to a high of $1070.9040 (Apr 15, 2026), with a median of $1070.9040 per ML.
Are there cheaper alternatives to PEGASYS 180 MCG/ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of PEGASYS 180 MCG/ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PEGASYS 180 MCG/ML VIAL?
PEGASYS 180 MCG/ML VIAL (NDC 82154044901) is labeled by pharmaand GmbH, and CMS classifies it as a brand product.
Is PEGASYS 180 MCG/ML VIAL in shortage?
Yes — NDC 82154044901 is currently listed in FDA's drug shortage database (posted Jan 24, 2025). Reported reason: Regulatory delay.